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A B S T R A C T
Sexual dimorphism, i.e. the distinct recognition of only two sexes per species, is the phenotypic expression of a multi-
stage procedure at chromosomal, gonadal, hormonal and behavioral level. Chromosomal – genetic sexual dimorphism
refers to the presence of two identical (XX) or two different (XY) gonosomes in females and males, respectively. This is due
to the distinct content of the X and Y-chromosomes in both genes and regulatory sequences, SRY being the key regulator.
Hormones (AMH, testosterone, Insl3) secreted by the foetal testis (gonadal sexual dimorphism), impede Müller duct de-
velopment, masculinize Wolff duct derivatives and are involved in testicular descent (hormonal sexual dimorphism).
Steroid hormone receptors detected in the nervous system, link androgens with behavioral sexual dimorphism. Further-
more, sex chromosome genes directly affect brain sexual dimorphism and this may precede gonadal differentiation.
Key words: SRY, Insl3, testis differentiation, gonads, androgens, AMH, Müller / Wolff ducts, aromatase, brain, be-
havioral sex
Introduction
Sex is a set model of anatomy and behavior, character-
ized by the ability to contribute to the process of repro-
duction. Although the latter is possible in the absence of
sex or in its multiple presences, the most typical pattern
and the one corresponding to humans is that of sexual di-
morphism. The term sexual dimorphism has been used
to describe morphological differences between the sexes,
but can be extended to any biologically-related process
that varies between males and females1.
This quality achieves to offer the necessary variability
in phenotype features, in gametogenesis and parental
chromosome fusion in fertilization, while at the same
time it ensures the maintenance of androgens and es-
trogens within an acceptable proportional ratio. Thus,
sexual dimorphism is the phenotypic expression of a mul-
tistage procedure at chromosomal, gonadal, hormonal
and behavioral level.
Chromosomal – Genetic Sexual Dimorphism
In humans, the typical male usually has a diploid
karyotype of 46 chromosomes, including 22 autosomal
pairs and an XY pair of gonosomes (46, XY). Alterna-
tively, a standard female karyotype would be 46, XX, the
latter referring to the two identical gonosomes in each
diploid cell.
The basis of sexual dimorphism in mammals derives
from the evolution of the sex chromosomes2. According
to recent findings, both X and Y chromosomes have
evolved from autosomal ancestors about 300 million
years ago3,4. At the time, a failure in homologous recom-
bination resulted in the formation of a small area that
wasn’t identical in the two chromosomes. The presence
or absence of this region coincided with a different pat-
tern of development that altered androgen activity, re-
sulting in a sex – determining role. In all mammalian or-
ganisms surviving today, this area appears to retain the
regulatory function and is therefore described as the
sex-determining region of the Y chromosome (SRY gene)5.
However, it must be pointed out, that the genetic basis of
sexual dimorphism is not limited to a single gene. In fact,
sequence analysis has suggested a gradual structural
conversion process. According to this theory, the X and Y
chromosomes have experienced repetitive recombination
failures throughout time, leading to the accumulation of
micro- and macroscopic specializations, which finally
lead to the extensive differentiation in the current struc-
ture of the two gonosomes4,6–8.
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The particularly small Y chromosome, in comparison
to its X partner, cannot be simply attributed to chromo-
somal recombination. Therefore, one must assume that
every failed recombination was followed by some level of
genomic instability, which caused partial deletions of the Y
chromosome-ancestor. Today, males carry a Y chromosome
that almost entirely (95%) consists of non-recombinant
sequences, allowing recombination with the X chromo-
some only in polar regions, the so-called pseudoautosomal
regions, PAR1 and PAR29. The non-recombinant region
(NRY) seems to have developed around the SRY gene to
include a variety of genes and regulatory elements that
cooperate to produce the main features of the male phe-
notype. Owing to this observation, it has recently been
proposed to rename this area as the male-specific region
of the Y chromosome, or MSY. Moreover, it has been sug-
gested that the MSY has the ability to exchange DNA be-
tween its own different units, allowing some level of vari-
ability. This unique quality is based on the presence of
palindromes, which increase its stability and determine
the positions of Y-Y recombination9–12. According to this,
one should expect that, the Y chromosome retains its
current length, after millions of years of gradual deterio-
ration, a concept that remains to be proven9,13,14.
For females, the double presence of the X chromo-
some seems to be related to sexual features. However, in
all higher mammals that have developed an MSY region,
extending the sex determining abilities of the SRY gene,
some model of X chromosome inactivation has been
employed15. This mechanism leads to dosage compensa-
tion between the two sexes for the large majority of
X-linked genes6. The remaining genes escape inactiva-
tion, which predisposes for their differentiated role in fe-
males, owing to their double expression from the two X
chromosomes, as opposed to a single copy in XY males.
However, not all of these genes have been found to con-
trol sex-related functions. Therefore, one may assume
that certain autosomal genes must also play an impor-
tant role in the establishment of the female sex pattern.
The crucial role of the sex chromosomes in dimor-
phism is particularly stressed by the phenotypic disorders
associated with cytogenetic alterations. Despite differ-
ences in their clinical manifestations, gonosome ane-
uploidies, such as Kleinefelter and Turner syndromes,
are always characterized by gonadal dysgenesis and in-
fertility.
Gonadal Sexual Dimorphism
The expression of the SRY gene is the key parameter
in gonadal differentiation. In males, SRY is expressed in
differentiating epithelial cells of the gonadal anlagen, i.e.
Sertoli cells that encompass germ cells forming the semi-
niferous cords16,17. SRY is expressed only briefly, and
therefore, one may assume that it acts as a form of mo-
lecular "switch", triggering a gene cascade that promotes
male phenotype (Table 1, Figure 1). Indeed, of the nu-
merous downstream genes, current research mainly fo-
cuses on two major gene products, both deriving from
Sertoli cells. The first is the SOX9 protein, which appears
to coordinate the formation of seminiferous cords within
the developing testis. The action of SOX is necessary for
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TABLE 1
MOLECULAR MARKERS IN THE EARLY STAGES OF GONADAL DIFFERENTIATION IN THE RAT FOETUS
Molecular markers Testis (XY) Ovary (XX) Molecular markers Testis (XY) Ovary (XX)
11.5 days post conception (dpc) 12.5 days post conception (dpc)
Sry + – Sry – –
SOX9 ++ – SOX9 ++ –
DAX1 ++ ++ DAX1 +/– ++
AMH – – AMH ++ –
Fig. 1. Genes implicated in gonadal sex differentiation.
normal testis development, since its absence totally in-
hibits it, regardless of SRY expression, as experiments
with mutant SOX deficient mice have shown. This in-
volves both Sertoli and Leydig cells, since the latter are
induced by SOX9 to express the FtzF1 gene, whose prod-
uct is the main regulator of androgen production, i.e.
steroidogenic factor 1 (SF1)18,19.
Although testis formation is largely androgen-inde-
pendent, it seems that subsequent development of the or-
gan depends on continuous trophic exposure to androgens.
The latter are produced by Leydig cells and accumulated
by the androgen binding protein produced by Sertoli
cells. Experimental data in adult rats show that a stable
androgen to estrogen ratio is vital to retain both ovary
and testis histological organization.
Testosterone promotes Wolffian duct differentiation
into the male reproductive tract through the formation
of the epididymides, vas deferentia and seminal vesicles.
On the other hand, Sertoli cells produce the Anti Mül-
lerian Hormone (AMH), shortly following SRY stimula-
tion. This hormone inhibits the development of the Mül-
lerian ducts in the male embryo20–22.
In females, absence of the SRY gene allows the forma-
tion of an ovary. Among the major regulators of this pro-
cess, one may refer to the DAX1 protein, which is associ-
ated with follicular cell function and the formation of the
primordial follicles. The importance of this product is un-
derstood by the result of its duplication in male rats. In
this case, regardless of SRY or SOX action, DSS-AHC
critical region on the X chromosome gene 1 (DAX1, also
known as NrOb1) achieves the feminization of the geni-
tal structures, a process described as dosage-sensitive sex
reversal23. In addition, experimental data suggest that its
presence, in small quantities, in males, may actually be
required for the initial organization of the epithelium
forming seminiferous cords. As far as ovaries are con-
cerned, steroid producing cells are represented by the in-
ner and outer theca. The SF1 protein is the key regulator
of androgen production in these cells as well, but it also
helps to limit P450 aromatase activity, thus achieving an
optimal androgen to estrogen ratio.
In the absence of male hormones, the Wolffian ducts
degenerate, whereas the Müllerian ducts persist and dif-
ferentiate into the female reproductive tract, including
the oviduct (fallopian tube), uterus, cervix and upper
portion of the vagina. Homeobox A (Hoxa) genes are ex-
pressed along the craniocaudal axis of the Müllerian
ducts and specify the identities of the developing struc-
tures. The expression of a lin-11, Isl1 and mec-3 ho-
mologue (Lim1, also known as Lhx1) which encodes a
LIM class homeodomain protein, in the epithelium of the
Wolffian andMüllerian ducts highlights the initial sexual
duality of the forming reproductive systems24,25.
Hormonal Sexual Dimorphism
The external genitalia and the secondary sex features,
such as osteology, muscular strength, voice depth, hair
length, lipid distribution pattern, facial characteristics
and breast development, are controlled by androgens and
estrogens26–29. Both types of hormones may act in andro-
gen and estrogen receptors, thus altering the outcome at
a cellular and tissue level. It is important to note that,
while estrogens mainly act in the form of estradiol, i.e.
the final product in the aromatase chain of reactions, an-
drogens act as both, testosterone, and the most enhanced
form, dihydrotestosterone (DHT). The latter is produced
from testosterone by the action of the enzyme 5a-re-
ductase. Testosterone and DHT bind to a specific high-
-affinity intracellular receptor and, ultimately, this hor-
mone-receptor complex enters the nucleus and modulates
transcription of tissue-specific genes and their protein
products. Testosterone-receptor complex mediates devel-
opment of the Wolffian derivatives whereas DHT-recep-
tor complex modulates differentiation of the urogenital
sinus and male external genitalia. The response of target
tissues to testicular hormones lasts for a particular de-
velopmental period, which constitutes the sensitive pe-
riod for hormone action. Hormonal treatment of females
in adulthood has negligible effects on genital morpho-
logy27. The differentiation of external genitalia into labia
majora, labia minora, clitoris and part of the vagina is
stimulated by estrogens. Androgens together with AMH
and insulin-like growth factor 3 (Insl3) are involved in
testicular descent to the scrotum, via activation of the
Lim1 transcriptional factor. In the female embryo, the
absence of androgen holds the ovary by the suspensory
ligament inside the abdomen and, as Insl3 is not present,
the gubernaculums fades away before it has a chance to
yank the ovary outside30.
Sexual Dimorphism of the Brain
Until recently, scientists believed that the way in
which each individual chooses to determine his/her sex
constitutes a final, "behavioral" level in sexual dimor-
phism, attributed to psychological rather than organic
factors. However, it has been suggested that sex hor-
mones might be involved in processes within the central
nervous system (CNS) which cannot explain sexual pref-
erences, but they may constitute some kind of predisposi-
tion to homo- or hetero-sexuality. This concept has given
rise to extensive research on this field of Neuroscience,
leading to reviews and original papers on the issue of the
so-called "sexual brain"31,32.
Of the various functional regions of the CNS, those
that seem to be closely associated with the sexual behav-
ior are the hypothalamus, the amygdala and the bul-
bocavernosus nucleus in the spinal cord. The hypothala-
mus represents a central area in the regulation of the
autonomous nervous system and the function of vital or-
gans. Regions related to sexual dimorphism, perinatally,
include the preoptic area and the anteroventral peri-
ventricular nucleus, both bearing estrogen receptors. On
the other hand, the septal AVP, the spinal bulbocaver-
nosus nucleus (SBN) and the nucleus robustus archis-
triatum seem to retain a role in sexual differentiation
throughout life. With the exception of the SBN, which
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only contains androgen receptors, the others seem to be
regulated by both androgen and estrogen receptors (glu-
tamate secreting neurons). This is true for the poste-
rodorsal medial amygdala in adults. Progesterone, on the
other hand, is known to bind to the subunit of GABA-
nergic neurons.
Although the exact target for sex hormone activity in
the CNS is not clear, research has provided some proba-
ble candidates. These include, for example, the ciliary
neurotrophic factor (CNTF) receptor, which regulates
neuronal development. Moreover, PGE2 may promote
"masculinization" of the preoptic area in the hypothala-
mus, but it cannot justify the differences in volume ob-
served between the two sexes. Granulin is an androgen-
-induced modulator of epithelial growth, highly expressed
in the ventromedial and arcuate nucleus of the hypo-
thalamus33. Prenatal exposure to high androgen concen-
trations is often found in the history of homosexual
women, while androgen insensitivity is detected in some
men submitted to surgical sex reversal.
Differences between male and female brains are thought
to arise largely through the actions of gonadal secretions
during a critical period of brain development34. In hu-
mans (as in rats) circulating testosterone displays 2
peaks. The 1st peak, in male human embryo, occurs in the
2nd trimester of gestation and the 2nd peak in the 1st year
of post-natal life (Figure 2). Thus, higher levels of testos-
terone during foetal and neonatal life cause the masculi-
nization of the brain31,32.
Due to the fact that, specific central nervous system
regions and behavior can be fully sex-reversed by treat-
ing females with testosterone or preventing the action of
testicular hormones in males, no other factor need to be
invoked in order to explain the sexual differentiation
process in those cases35.
Testis-Dependent Sexual Dimorphism
Several masculinizing effects of androgens in the
brain result from aromatization of testosterone to estro-
gen, catalyzed by aromatase, an enzyme abundant in the
hypothalamus36. Only aromatizable androgens, such as
testosterone, exert a masculinizing effect in female rats,
not non-aromatizable androgens, such as 5
-dihydro-
testosterone (5
-DHT). But, in addition to aromatase,
the brain contains 5
-reductase. The type 2 isoform of
5
-reductase (5
-R2) is expressed in cerebral neurons
and its maximal expression occurs a few days after birth,
in males than in females. This enzyme (5
-DHT) seems
to be a morphogenetic signal for the development of
aromatase-expressing neurons of the hypothalamus32.
However, the importance of 5
-DHT in brain mascu-
linization is limited because men with homozygous inac-
tivation of the 5
-R2 gene and their animal model (5
-R2
knock-out mice) display a proper gender identity and
behavior37,38.
Lesions of the entire preoptic area (POA) in the ante-
rior hypothalamus eliminate virtually all male copula-
tory behaviors, whereas lesions restricted to the sexually
dimorphic nucleus of the POA (SDN-POA) have more
modest effects. Treating female rats with testosterone,
just before and after birth, causes the SDN-POA in
adulthood to be as large as in normal males, whereas cas-
trating male rats at birth results in a smaller feminine
SDN-POA in adulthood. Thus, sexual differentiation of
this nucleus resembles that of the genitalia, i.e. androgen
early in life permanently masculinize this brain regi-
on39–41.
However, a divergence has been observed on these neu-
ral sexual dimorphisms. Some rely on perinatal actions of
testosterone (SDN-POA, AVPV) and some require both
perinatal and adult testosterone (septal vasopressin, BNST,
SNB, RA)34. Yet, others require testosterone only in
adulthood (MePD – Prostero Dorsal Medial Amygdala)41, 42.
In some cases, testosterone acts only on estrogen recep-
tors (SDN-POA, AVPV) or activates both androgen and
estrogen receptors (septal vasopressin, MePD, RA)43, 44.
In other cases, only androgen receptors act perinatally
(SNB).
Testis-Independent Sexual Dimorphism
Recent studies have shown that, sex-specific differ-
ences observed in both mammals and birds can be associ-



















































Fig. 2. Levels of testosterone in foetal and neonatal a) rats and
b) humans: dpc – days post conception, dpp – days post partum.
a)
b)
ated with X and Y chromosome-linked genes acting di-
rectly on the brain cells45. In several species of songbirds,
males sing more than females, a functional difference
that matches a structural difference: the forebrain re-
gions controlling song, including the Higher Vocal Cen-
ter (HVC) and the nucleus Robustus Archistriatum (RA).
These nuclei are much larger in males and contain larger
neurons, than their female counterparts. The forebrain
song circuit shows marked sexual differentiation, which
does not seem to be due solely to gonadal hormones, but
rather might result from differences in neuronal sex
chromosome genotype46.
Manipulating males with gonadal estrogen do not
prevent masculine development, so it seems that brain
cells may produce de novo estrogen (neurosteroids) to in-
duce HVC ingrowth and masculine development. Neuro-
nal transplantation studies in quails also support a role
for genetic sex in controlling sexual differentiation in the
brain. This means that, an important contribution to the
process of brain sexual dimorphism is given by the action
of sex chromosome genes, acting locally, within the brain
(somatic) cells and steroid hormones are produced in
situ, to virilize the bird song system47.
Microarray screening of genes that were expressed
differentially in the brain of male and female mice, be-
fore gonadal hormone secretion, allowed the identifica-
tion of 57 female enhanced genes and 24 male enhanced
genes, at embryonic day 10.5 (E10.5). This means that
sexual differences in gene expression in neuronal cells,
before gonadal hormone secretion, play an important
role in sexual dimorphism in the brain48,49.
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SPOLNI DIMORFIZMA KOD LJUDI
S A @ E T A K
Spolni dimorfizam, odnosno raspoznavanje dvaju spolova unutar vrste, fenotipska je ekspresija vi{efaznog postupka
na kromosomskoj, gonadnoj, hormonalnoj i bihevioralnoj razini. Kromosomsko-genetski spolni dimorfizam odnosi se
na postojanje dvaju identi~nih (XX) ili dvaju razli~itih (XY) gonosoma kod `ena i mu{karaca. To je posljedica razli~itog
sadr`aja X i Y kromosoma na oba gena te regulatorskih sekvenci, a SRY je klju~ni regulator. Hormoni (AMH, testoste-
ron, Insl3) koje izlu~uju fetalni testisi (gonadni spolni dimorfizam) prije~e razvoj Müllerovog duktusa, maskuliniziraju
derivate Wolffovog duktusa te su uklju~eni u testikularno propadanje (hormonalni spolni dimorfizam). Receptori ste-
roidnih hormona, na|eni u `iv~anom sustavu, ve`u androgene uz bihevioralni spolni dimorfizam. Nadalje, geni na
spolnim kromosomima direktno utje~u na mo`dani bihevioralni dimorfizam, {to mo`e prethoditi gonadnoj diferen-
cijaciji.
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